International Conference on Harmonisation; guidance on S7A safety pharmacology studies for human pharmaceuticals; availability. Notice
- PMID: 12356097
International Conference on Harmonisation; guidance on S7A safety pharmacology studies for human pharmaceuticals; availability. Notice
Abstract
The Food and Drug Administration (FDA) is announcing the availability of a guidance entitled "S7A Safety Pharmacology Studies for Human Pharmaceuticals." The guidance was prepared under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The guidance provides a definition, general principles, and recommendations for the nonclinical safety pharmacology studies. The guidance is intended to help protect clinical trial participants and patients receiving marketed products from potential adverse effects of pharmaceuticals, while avoiding unnecessary use of animals and other resources.
Similar articles
-
International Conference on Harmonisation; choice of control group and related issues in clinical trials; availability. Notice.Fed Regist. 2001 May 14;66(93):24390-1. Fed Regist. 2001. PMID: 12356096
-
International Conference on Harmonisation; Guidance on M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals; availability. Notice.Fed Regist. 2010 Jan 21;75(13):3471-2. Fed Regist. 2010. PMID: 20349552
-
International Conference on Harmonisation; Guidance on S9 Nonclincal Evaluation for Anticancer Pharmaceuticals; availability. Notice.Fed Regist. 2010 Mar 8;75(44):10487-8. Fed Regist. 2010. PMID: 20383918
-
ICH S9: Developing anticancer drugs, one year later.Toxicol Pathol. 2011 Oct;39(6):913-5. doi: 10.1177/0192623311416263. Epub 2011 Aug 22. Toxicol Pathol. 2011. PMID: 21859887 Review.
-
Regulatory aspects of oncology drug safety evaluation: past practice, current issues, and the challenge of new drugs.Toxicol Appl Pharmacol. 2010 Mar 1;243(2):125-33. doi: 10.1016/j.taap.2009.12.020. Epub 2010 Jan 4. Toxicol Appl Pharmacol. 2010. PMID: 20045015 Review.
Cited by
-
Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.Circulation. 2013 Apr 23;127(16):1677-91. doi: 10.1161/CIRCULATIONAHA.113.001883. Epub 2013 Mar 21. Circulation. 2013. PMID: 23519760 Free PMC article.
-
A PDE10A inhibitor CPL500036 is a novel agent modulating striatal function devoid of most neuroleptic side-effects.Front Pharmacol. 2022 Nov 9;13:999685. doi: 10.3389/fphar.2022.999685. eCollection 2022. Front Pharmacol. 2022. PMID: 36438799 Free PMC article.
-
Experimentally Validated Pharmacoinformatics Approach to Predict hERG Inhibition Potential of New Chemical Entities.Front Pharmacol. 2018 Sep 19;9:1035. doi: 10.3389/fphar.2018.01035. eCollection 2018. Front Pharmacol. 2018. PMID: 30333745 Free PMC article.
-
Heart Rate Correction of the J-to-Tpeak Interval.Sci Rep. 2019 Oct 21;9(1):15060. doi: 10.1038/s41598-019-51491-4. Sci Rep. 2019. PMID: 31636317 Free PMC article.
-
Influence of heart rate correction formulas on QTc interval stability.Sci Rep. 2021 Jul 12;11(1):14269. doi: 10.1038/s41598-021-93774-9. Sci Rep. 2021. PMID: 34253795 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical